Evidence map›Paper›PMID 37178203›Full record

ArticleEuropean radiology2023

Role of MRI radiomics for the prediction of MYCN amplification in neuroblastomas.

Adarsh Ghosh, Ensar Yekeler, Sara Reis Teixeira, Deepa Dalal, Lisa States

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Radiomics-Based Machine Learning for DeterminingTechnology in cancer research & treatment
    Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Adarsh GhoshDepartment of Radiology, Cincinnati Children's Hospital and Medical Centre, Cincinnati, OH, USA. adarsh11g11@icloud.com.ORCID http://orcid.org/0000-0002-9325-2762
Ensar YekelerDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Sara Reis TeixeiraDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Deepa DalalDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Lisa StatesDepartment of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Children's Hospital of Philadelphia · USCincinnati Children's Hospital Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe evaluate MR radiomics and develop machine learning-based classifiers to predict MYCN amplification in neuroblastomas.

methodsA total of 120 patients with neuroblastomas and baseline MR imaging examination available were identified of whom 74 (mean age ± standard deviation [SD] of 6 years and 2 months ± 4 years and 9 months; 43 females and 31 males, 14 MYCN amplified) underwent imaging at our institution. This was therefore used to develop radiomics models. The model was tested in a cohort of children with the same diagnosis but imaged elsewhere (n = 46, mean age ± SD: 5 years 11 months ± 3 years 9 months, 26 females and 14 MYCN amplified). Whole tumour volumes of interest were adopted to extract first-order histogram and second-order radiomics features. Interclass correlation coefficient and maximum relevance and minimum redundancy algorithm were applied for feature selection. Logistic regression, support vector machine, and random forest were employed as the classifiers. Receiver operating characteristic (ROC) analysis was performed to evaluate the diagnostic accuracy of the classifiers on the external test set.

resultsThe logistic regression model and the random forest both showed an AUC of 0.75. The support vector machine classifier obtained an AUC of 0.78 on the test set with a sensitivity of 64% and a specificity of 72%.

conclusionThe study provides preliminary retrospective evidence demonstrating the feasibility of MRI radiomics in predicting MYCN amplification in neuroblastomas. Future studies are needed to explore the correlation between other imaging features and genetic markers and to develop multiclass predictive models. KEY POINTS: • MYCN amplification in neuroblastomas is an important determinant of disease prognosis. • Radiomics analysis of pre-treatment MR examinations can be used to predict MYCN amplification in neuroblastomas. • Radiomics machine learning models showed good generalisability to external test set, demonstrating reproducibility of the computational models.

Indexed as

Magnetic Resonance ImagingNeuroblastomaChildFemaleHumansMaleN-Myc Proto-Oncogene ProteinReproducibility of ResultsRetrospective StudiesMYCN protein, humanN-Myc Proto-Oncogene ProteinMachine learningMagnetic resonance imagingNeuroblastomaN-MYC proto-oncogene protein

Identifiers

PMID37178203
OpenAlexW4376504560

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.